Case report reveals rebound hypercalcemia post denosumab therapy in an 8-year-old child, suggesting need for preventive strategies.
Denosumab has been successfully used as an off-label therapy for the treatment of pediatric aneurysmal bone cysts. Severe hypercalcemia after cessation of denosumab therapy has been reported in a few case reports in the literature. It is imperative to understand the causative factors, management options, and preventive strategies of rebound hypercalcemia after denosumab withdrawal in pediatric patients. We report an 8-year-old male child who presented to us with severe rebound hypercalcemia 3 months post cessation of denosumab therapy.
No takes yet. Share an insight, caveat, or question.
V Shobi Anandi (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: